Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lyka LabsBOM:500259 -4.57%51 Days Inventory is 112.76 as of Mar. 2026, which is 55% above its 10-year median of 72.69. GuruFocus rates BOM:500259 with a GF Score™ of 51/100 and a GF Value™ of ₹127.58 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 637 Biotechnology companies, Lyka Labs ranks better than 73.63% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Lyka Labs's Average Total Inventories for the
three
months ended in Mar. 2026 was ₹136 Mil. Lyka Labs's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ₹110 Mil.
Hence, Lyka Labs's Days Inventory for the
three
months ended in Mar. 2026 was 112.76.
The historical rank and industry rank for Lyka Labs's Days Inventory or its related term are showing as below:
BOM:500259'
s Days Inventory Range Over the Past 10 Years
Min: 42.81 Med: 72.69 Max: 151
Current: 91.21
During the past 13 years, Lyka Labs's highest Days Inventory was 151.00. The lowest was 42.81. And the median was 72.69.
BOM:500259's Days Inventory is ranked better than 73.63% of 637
companies
in the Biotechnology industry
Industry Median: 183.16
vs BOM:500259: 91.21
Lyka Labs's Days Inventory
increased
from Mar. 2025 (86.93) to Mar. 2026 (112.76).
It might indicate that Lyka Labs's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Lyka Labs's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.81.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Lyka Labs's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.49.
Lyka Labs (BOM:500259) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Lyka Labs's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Lyka Labs's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Lyka Labs Days Inventory Related Terms
Lyka Labs Days Inventory Historical Data
* Premium members only.
The historical data trend for Lyka Labs's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500259 vs VRTX, REGN, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, Lyka Labs's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyka Labs Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyka Labs's Days Inventory distribution charts can be found below:
* The bar in red indicates where Lyka Labs's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyka Labs (BOM:500259) has a Days Inventory of 112.76 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Lyka Labs and its competitors. This is 55% above median its historical median of 72.69. Over the past decade, Lyka Labs' Days Inventory has ranged from 42.81 to 151.00. According to the industry distribution chart, Lyka Labs ranks #168 out of 637 companies in the Biotechnology industry, placing it in the top 26.4%.
Is Lyka Labs' Days Inventory too high?
Lyka Labs' current Days Inventory of 112.76 is 55% above median its 10-year median of 72.69. Over the past 10 years, this metric has ranged from a low of 42.81 to a high of 151.00. The Biotechnology industry median Days Inventory is 183.16. Lyka Labs' value of 112.76 is 38.4% below this industry median. Based on the distribution chart, Lyka Labs ranks #168 out of 637 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lyka Labs has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lyka Labs ranks #168 out of 637 companies for Days Inventory. This puts Lyka Labs in the upper half of its industry. The industry median Days Inventory is 183.16. Lyka Labs' value of 112.76 is 38.4% below this benchmark. Historically, Lyka Labs' own Days Inventory has ranged from 42.81 to 151.00 over the past decade. While the company's 10-year median is 72.69 vs. the industry median of 183.16, Lyka Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.16, based on 637 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lyka Labs's current Days Inventory of 112.76 is 38.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Lyka Labs and its competitors. For the Biotechnology industry, the median Days Inventory is 183.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lyka Labs's current Days Inventory is 112.76, which is 55% above median its own 10-year median of 72.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (BOM:500259) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹127.58, compared to a current price of ₹61.98 — trading 51.4% below its estimated fair value. The current Days Inventory is 112.76, which is 55% above median its 10-year median of 72.69 and 38.4% below the Biotechnology industry median of 183.16. Lyka Labs' overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Lyka Labs (BOM:500259), the current Days Inventory is 112.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyka Labs (BOM:500259) Overvalued in 2026?
Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued.
The current stock price of ₹61.98 is trading 51.4% below its estimated GF Value™ of ₹127.58.
GuruFocus considers Lyka Labs to be Significantly Undervalued.
Key valuation signals for BOM:500259:
Days Inventory: 112.76 (55% above median its 10-year median of 72.69)
GF Value™: ₹127.58 vs. price of ₹61.98 (51.4% below fair value)
Industry Position: 38.4% below the Biotechnology median (#168 of 637)
No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
51GF Score
Get the complete analysis for BOM:500259
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500259 has been successfully added to your 
